<DOC>
	<DOCNO>NCT00603408</DOCNO>
	<brief_summary>The purpose study determine whether Cisplatin give radiation therapy prior surgery effective improve response treatment breast cancer patient . Tumor , blood bone marrow sample collect study also help researcher determine cisplatin able change tumor DNA multiply create tumor cell , cause tumor cell die .</brief_summary>
	<brief_title>Effect Chemotherapy Radiation Prior Surgery Triple Negative Breast Cancer</brief_title>
	<detailed_description>After Diagnosis : Clinical Stage IIB , III Breast Cancer , Triple Negative Week 0 : Port-A-Cath placement Tumor biopsy ( Core FNA ) Blood collection Bone marrow aspiration Sentinel Lymph node biopsy , axillary US negative Week 1 : Chemo &amp; Radiation Day 1 : Radiation Therapy , Cisplatin 75mg/m^2 ( cycle 1 ) Days 2-5 : Radiation Therapy Week 2 : Radiation Day 1-5 : Radiation Therapy Week 3 : Radiation Days 1-5 : Radiation Therapy Week 4 : Chemo &amp; Radiation Day 1 : Radiation Therapy , Cisplatin 75mg/m^2 ( cycle 2 ) Days 2-5 : Radiation Therapy Week 5 : Radiation Days 1-5 : Radiation Therapy Week 6 : Radiation Days 1-5 : Radiation Therapy Week 7 : Chemo Day 1 : Cisplatin 75mg/m^2 ( cycle 3 ) Week 10 : Chemo Day 1 : Cisplatin 75mg/m^2 ( cycle 4 ) Week 13 : Surgery Mastectomy with/without axillary lymph node dissection Tumor biopsy ( Core FNA ) Blood collection Bone marrow aspiration Week 15 - 21 : Recommended ( physician discretion ) Adjuvant Chemo Dose dense Doxorubicin : 60mg/m^2 &amp; Cyclophosphamide : 600mg/m^2 , every 2 week 4 cycle Week 21 - 29 : Recommended ( physician discretion ) Adjuvant Chemo Paclitaxel : 175mg/m^2 every 2 week 4 cycle Week 52 IVAD Removal , Bone marrow aspiration Follow-Up ( 5 year ) Q 3 month year 1 Q 6 month year 2-3 Q 1 year year 4-5</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients must &gt; = 18 year age Patients must newly diagnose primary invasive ductal breast adenocarcinoma . Tumor classify clinically stage T2 , T3 T4 N ( NX , N1 , N2 , N3 ) . Tumor express follow biomarkers : estrogen receptor , progesterone receptor , Her2/neu Adequate organ function define : Serum Creatinine &lt; = 1.5 x upper limit institutional normal . ALT , AST , ALK Phos &lt; = 1.5 x upper limit institutional normal . Bilirubin &lt; = 1.5 x upper limit institutional normal . Normal leave ventricular function ( LVEF &gt; 50 % ) MUGA ECHO . No evidence distant metastasis present CT , Bone scan , physical exam . If bone scan CT scan demonstrate indeterminate lesion , nature lesion clarify additional testing PET MRI . No prior malignancy exception curatively treat basal squamous carcinoma skin history previous malignancy , treat least great 5 year disease free survival . Women child bear potential may currently pregnant breastfeed time registration must agree use adequate contraception . Karnofsky Performance Status &lt; = 70 . Patients known history neural deficiency ( e.g . peripheral neuropathy ) . Patients know hearing impairment ( hearing loss severe tinnitus ) . Male patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Locally Advanced</keyword>
	<keyword>Neoadjuvant</keyword>
</DOC>